Preview

Медицинский Совет

Расширенный поиск

АМАНТАДИНЫ: ОПЫТ ПРИМЕНЕНИЯ ПРИ БОЛЕЗНИ ПАРКИНСОНА

https://doi.org/10.21518/2079-701X-2016-11-52-56

Полный текст:

Аннотация

В статье описывается зарубежный и отечественный опыт применения амантадина и препарата ПК-Мерц при болезни Паркинсона в качестве монотерапии и комплексного лечения. Приводятся данные основных плацебо-контролируемых исследований эффективности и безопасности препаратов данной группы.

Об авторах

А. А. ПИЛИПОВИЧ
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
к.м.н.


В. Л. ГОЛУБЕВ
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
д.м.н., профессор


Список литературы

1. Карабань И.Н., Карабань Н.В., Карасевич Н.В. Блокаторы глутаматных рецепторов (Неомидантан) в патогенетической терапии болезни Паркинсона и других неврологических заболеваний. Методические рекомендации. Киев. 2009. 23 с.

2. Schwab RS, England AC, Poskanzer DC et al. Amantadine in the Treatment of Parkinson's Disease. JAMA, 1969, 7: 1168-1170.

3. Silver DE, Sahs AL. Double blind study using amantadine hydrochloride in the therapy of Parkinson’s disease. Trans Am Neurol Assoc, 1971, 96: 307-308.

4. Verhagen Metman L, Del Dotto P, van den Munckhof P et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology, 1998, 50: 1323-1326.

5. Verhagen Metman L, Del Dotto P, LePoole K et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol, 1999, 56: 1383-1386.

6. Wolf E, Seppi K, Katzenschlager R et al. Longterm antidyskinetic efficacy of amantadine in Parkin son’s disease. Mov Disord, 2010, 25: 1357-1363.

7. Pahwa R, Tanner CM, Hause RA et al. Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASED Study). Movement Disorders, 2015, 6: 788-795.

8. Кривонос О.В., Амосова Н.А., Смоленцева И.Г. Применение антагониста глутаматных NMDA-рецепторов ПК-Мерц в остром периоде инсульта. Журн. неврологии и психиатрии им. С.С. Корсакова, 2009, 4: 72-74.

9. Румянцева С.А., Боневольская Н.Г. Новые направления в патогенетической терапии инсульта. Атмосфера. Нервные болезни: журнал для практич. Врачей, 2006, 4: 29-34.

10. Meythaler JM, Brunner RC, Johnson A et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J. Head Trauma Rehabil., 2002, 4: 300-313.

11. Steube D, Gortelmeyer R. The influence of amantadine sulfate on disturbances of arousal after severe traumatic brain injury. Neurology, 2000, 6: 307-312.

12. Quack G, Hesselink M, Danysz W, et al. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl, 1995, 46: 97-105.

13. Maj J, Sowinska H, Baran L. The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia, 1972, 2: 296-307.

14. Dallos V, Heathfield K, Stone P et al. Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial. Br Med J, 1970, 4: 24-6.

15. Greulich W, Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm Suppl, 1995, 46: 415-421.

16. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebocontrolled, crossover study with long-term follow-up. Neurology, 1975, 7: 603-606.

17. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson’s disease: the facts about the myth. Mov Disord, 1999, 3: 515-517.

18. Chung JS, Wu AD, Lew MF. Amantadine and Anticholinergics. U.S.A. Copyright 2003 by Marcel Dekker, Inc. All Rights Reserved. 18 P.

19. Parkinson’s disease Diagnosis and management in primary and secondary care / Developed by the National Collaborating Centre for Chronic Conditions. National Institute for Health and Clinical Excellence, 2006, 35: 1-45.

20. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology, 1975, 25(8): 695-700.

21. Verhagen Metman L, Del Dotto P, van den Munckhof P et al. Amantadine as treatment for dyski-nesias and motor fluctuations in Parkinson’s disease. Neurology, 1998, 5: 1323-1326.

22. Engber TM, Papa SM, Boldry RC et al. NMDA receptor blockade reverses motor response alterations induced by L-dopa. NeuroReport, 1994, 5: 2586-2588.

23. Papa SM, Chase TN. L-dopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol, 1996, 39: 574-578.

24. Rajput AH, Rajput A, Lang AE, et al. New use for an old drug: amantadine benefits L-dopa-induced dyskinesias. Mov Disord, 1998, 13: 851-854.

25. Del Dotto P, Pavese N, Gambaccin G et al. Intravenous Amantadine Improves LevadopaInduced Dyskinesias: An Acute Double-Blind Placebo-Controlled Study. Movement Disorders, 2001, 16(3): 515-520.

26. Hideyuki Sawada, Tomoko Oeda, Sadako Kuno et al. Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial. PLoS One, 2010, 5(12): e15298.

27. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol, 2000, 23: 82-85.

28. Luginger E, Wenning GK, Bösch S et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord, 2000 Sep, 15(5): 873-878.

29. Haoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokin, 1988, 14: 35-51.

30. Thomas A, Iacono D, Luciano AL et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry, 2004 Jan, 75(1): 141-143.

31. Ory-Magne F, Corvol JC, Azulay JP et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology, 2014, 4: 300-307.

32. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev, 2003, 2: CD003467.

33. Obeso J, Rodriguez-Oroz MC, Rodriguez M et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol, 2000, 47(Suppl 1): 22-34.

34. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG. Alteration in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol, 2000, 57: 342-352.

35. Ciliax BJ, Greenamyre JT, Levey AI. Functional biochemistry and molecular neuropharmacology of the basal ganglia and motor systems. In: Watts RL, Koller WC, eds. Movement disorders. Neurological principles and practice. New York: MacGraw Hill, 1997: 99-116.

36. Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson’s disease. Mov Disord, 1993, 8: 512-514.

37. Uitti RJ, Rajput AH, Ahlskog JE et al. Amantadine treatment is an independent predictor of improved survival in Parkinson’s Disease. Neurology, 1996, 6: 1551-1556.

38. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson’s disease. Mol Neurobiol, 1996, 12(1): 73-94.

39. Turski L, Bressler K, Rettig KJ et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 1991, 349(6308): 414-418.

40. Mehta K, Martin J, Costello I et al. Amantadine Hydro - chloride. British National Formulary, 2005, 49: 251.

41. Crosby NJ, Deane K, Clarke CE. Amantadine in Parkinson’s disease (Review). The Cochrane Collaboration, 2009: 1-22.

42. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson’s disease: a review of the literature and a case report. Mov Disord, 1998, 13(1): 34-38.

43. Никонов В.В., Савицкая И.Б. Роль антагонистов глутаматных рецепторов (ПК-Мерц) в лечении повреждений мозга. Медицина неотложных состояний, 2012, 5(44).

44. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl, 1995, 46: 399-405.

45. Brenner M, Haass A, Jacobi P, Schimrigk K. Intravenous and oral treatment with amantadine sulfate in Parkinson disease. Nervenarzt, 1988, 3: 180-184.

46. Бойко А.Н., Барышева Т.Т., Викина Е.С. и др. Эффективность использования ПК-Мерца при болезни Паркинсона в амбулаторной практике. Лечение нервных болезней, 2004, 2: 20.

47. Muller T, Kuhn W, Schulte T et al. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci. Lett., 2003, 339: 2528.

48. Федорова Н.В., Ветохина Т.Н. Диагностика и лечение нейролептических экстрапирамидных синдромов: Учебно-методическое пособие. М.: РАМПО, 2006, 36 с.

49. Карабань И.Н. Применение блокатора глутаматных рецепторов амантадина в неврологии. Международный неврологический журнал, 2012, 2(48).

50. Onofrj M, Frazzini V, Bonanni L et al. Amantadine and antiglutamatergic drugs in the management of Parkinson’s disease. In: Parkinson’s Disease. Current and Future Therapeutics and Clinical Trials, Galvez-Jimenez et al. (Ed), Cambridge University Press. 2016, pp. 13-22.


Просмотров: 239


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)